AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04429165 — intervention group
Intervention type: OTHER
Intervention: collection of anthropometric and clinical functional data
Description: collection of anthropometric and clinical functional data including range of motion (ROM), isokinetic muscle strength, joint position sense, single leg balance ability, and muscle activity
Study NCT04429165 — intervention group
Intervention type: OTHER
Intervention: gait analysis
Description: gait analysis in a motion capture volume on a walkway including force plates and on a treadmill with pressure plates, while 3D kinematics and kinetics, pressure and electromyographic (EMG) data will be recorded
Study NCT02613884 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment
Study NCT02355249 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MIE
Description: Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
Study NCT02355249 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: OE
Description: Patients will be treated with traditional three incisions esophagectomy.
Study NCT03725579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mepivicane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation
Study NCT03725579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mepivicane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation
Study NCT03725579 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: articane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation
Study NCT03725579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: articane hydrochloride
Description: Pain will be assessed during access cavity preparation and instrumentation
Study NCT04200235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride nasal spray
Description: In the low weight group, 18 subjects will receive a low dose of dexmedetomidine nasal spray.~In the high weight group, 18 subjects will receive a high dose of dexmedetomidine nasal spray.
Study NCT04200235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride nasal spray blank preparation.
Description: In the low weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.~In the high weight group, 6 subjects will receive dexmedetomidine hydrochloride nasal spray blank preparation.
Study NCT01966614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRX302
Description: Single intraprostatic bilateral injection at a dose of 0.6 µg/g
Study NCT01924338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
Study NCT01924338 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser scan
Description: A near-infrared laser scan of the subject's forehead is acquired
Study NCT01924338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dental cast creation
Description: A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
Study NCT03886896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine infusion during surgery
Study NCT05784493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study group
Description: Washing by heated saline group
Study NCT01966614 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single intraprostatic bilateral injection of vehicle only
Study NCT02429726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAdp53
Description: Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
Study NCT02429726 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin will be administered by intra chest cavity infusion
Study NCT02429726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAdp53 plus cisplatin
Description: Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
Study NCT02224313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral estradiol 1.0 mg
Description: one tablet of oral estradiol 1.0 mg once a day for 28 days
Study NCT02224313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral progesterone 100 mg
Description: one tablet of oral progesterone 100 mg once a day for 14 days
Study NCT00770770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.2 µg/day
Study NCT00770770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluocinolone Acetonide
Description: 0.5 µg/day
Study NCT01439542 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation
Description: Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week~Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week
Study NCT01439542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luteinizing Hormone Releasing Hormone (LHRH) Agonist
Description: 12 months (2x6 month depot) of androgen suppression with LHRH agonist
Study NCT03568045 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard light
Description: usual care
Study NCT03568045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright light, 4 hours
Description: Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to noon.
Study NCT03568045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 10,000 lux bright light, 8 hours
Description: Bright light will be delivered by a free-standing 10,000 lux device that will be positioned next to the patient's head of bed. At the estimated distance of 36 inches from light source to the patient, we anticipate approximately a 1,250 lux dose at the patient's eye. Light will be delivered from 8am to 4pm.
Study NCT02700412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex oral solution (100 mg/mL CBD concentration) with inactive ingredients including anhydrous ethanol, sesame seed oil, strawberry flavor, and sucralose).
Study NCT01440270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant Erbitux-based chemotherapy
Description: Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m\^2 initial, and then 250 mg/m\^2 weekly Route: Intravenous infusion Frequency \& treatment mode: Weekly Duration: 6 weeks~Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m\^2 Route: Intravenous infusion Frequency \& treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)~Arms: Neo-adjuvant Erbitux-based chemotherapy
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit antithymocyte globulin
Description: Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil
Description: Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
Study NCT00596947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate mofetil
Description: Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
Study NCT02484976 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Based Behavioral Treatment
Description: Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
Study NCT02685423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Binocular deprivation 10 days
Description: Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
Study NCT02685423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Vision training
Description: Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
Study NCT02685423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vision training
Description: Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
Study NCT03399136 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Participants attended center-based exercise sessions three times per week at the research exercise training facility located at the Baltimore VA Medical Center. All exercise training was performed under the supervision of research exercise physiologists. Heart rate (HR) was measured continuously during each session using a Polar HR watch and chest strap allowing for assessment and maintenance of treatment fidelity. Exercise logs included details on exercise type, duration, time in target heart rate zone, blood pressure and perceived intensity during each training session.
Study NCT02723695 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of postural performances
Description: Postural tests
Study NCT02723695 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of postural performances
Description: Postural tests
Study NCT03936283 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: The goal of the intervention is to help women increase their minutes of moderate-to-vigorous physical activity and to increase their knowledge of the IOM gestational weight gain guidelines. The lifestyle intervention will be delivered through telephone counseling sessions with a study dietician trained in motivational interviewing techniques, as well as through technology-based tools, automated text messages and core lifestyle intervention sessions.
Study NCT03683277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib/Pomalidomide/Dexamethasone
Description: Treatment with association of Ixazomib, Pomalidomide and Dexamethasone (IPD)~Induction phase : 21-days cycles - maximum of 17 cycles Ixazomib (tablets) 3 mg D1, D4, D8 and D11 Pomalidomide (tablets) 4mg D1 to D14 Dexamethasone (tablets) 40 mg/d D1, D8 and D15 if patient aged \<75 years Dexamethasone (tablets) 20 mg/d D1, D8 and D15 if patient aged ≥ 75 years~Treatment with association of Ixazomib and Pomalidomide (IP) Maintenance phase : 28-days cycles until disease progression Ixazomib (tablets) 4mg D1, D8 and D15 Pomalidomide (tablets) 4mg D1 to D21
Study NCT01547585 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standardized soy containing muffin
Description: Standardized muffin containing two levels of soy
Study NCT01547585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized soy containing muffin
Description: Standardized muffin containing two levels of soy
Study NCT04354480 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive single IM injection of Ad26.preF RSV based vaccine on Day 1.
Study NCT04354480 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of matching placebo on Day 1.
Study NCT03782402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoids
Description: Cannabinoids with THC and CBD versus placebo cannabinoids
Study NCT03782402 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cannabinoids
Description: Cannabinoids with THC and CBD versus placebo cannabinoids
Study NCT05067322 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Minecraft
Description: A game played within the videogame Minecraft
Study NCT05067322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Minecraft
Description: A game played within the videogame Minecraft
Study NCT02616549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sudarshan Kriya Yoga
Description: A manual-based yoga program featuring a yoga-breathing meditation technique
Study NCT04272658 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: value of 4D body-to-whole dynamic acquisition in FDG
Description: differentiate pseudo-progression / progression during the first therapeutic assessment by FDG PET / CT (PET1) using data from the 4D whole-body dynamic acquisition, without having to re-evaluate closely. during a PET1 'this unconfirmed progression after 2 new treatment cures of ICI
Study NCT04603131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Chikungunya virus vaccine 20 mcg
Description: 3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
Study NCT04603131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Chikungunya virus vaccine 30 mcg
Description: 3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
Study NCT04603131 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Chikungunya virus vaccine 10 mcg
Description: 3 doses of Inactivated Chikungunya virus vaccine (BBV87) administered intramuscularly on Day 0, 29 and 57
Study NCT04603131 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 doses of Placebo administered intramuscularly on Day 0, 29 and 57
Study NCT03938779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Muscle Training (PFMT)
Description: PFMT is a protocol of exercises for prevention and treatment for Stress Urinary Incontinence in elite females athletes, volleyball team
Study NCT03938779 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pad test
Description: Pad test is a standardised test for quantifying urine loss. Pad test is not invasive and provide an easy, inexpensive and objective assessment of urine loss.
Study NCT02300948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PregVit® contains 1.1 mg of folic acid
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
Study NCT02300948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PregVit-folic 5® contains 5 mg of folic acid
Description: Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
Study NCT02518997 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parental Reading Aloud
Description: Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
Study NCT01224626 — intervention group
Intervention type: DRUG
Intervention: Zyvox (linezolid)
Description: Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
Study NCT01737385 — intervention group
Intervention type: PROCEDURE
Intervention: Measurement with O2C
Description: Measurement of microcirculation using O2C light probes.
Study NCT01496131 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Description: Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
Study NCT01496131 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.